| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15, 2025 | LQDA Liquidia Corp | Kaseta Michael57 | CFO And COO | Sell | 20,000 | $26.18 | $523,674.00 | -5.3% | +3.8% | - | |
| Aug 15, 2025 | EOLS Evolus, Inc. | Stewart Brady | Director | Buy | 30,000 | $6.82 | $204,486.00 | +51.2% | +9.5% | - | |
| Aug 15, 2025 | ANIP Ani Pharmaceuticals Inc | Shanmugam Muthusamy59 | Head Of R&D, Coo-novitium Ops | Sell | 100,000 | $88.25 | $8,824,533.30 | -8.2% | -3.3% | - | |
| Aug 15, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Konidaris Tasos | Executive Vice President &CFO | Sell | 499,730 | $9.33 | $4,663,070.47 | -35.1% | +21.9% | - | |
| Aug 14, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Shah Nikita53 | Executive Vice President | Sell | 71,694 | $9.29 | $666,037.26 | -21.2% | +26.7% | - | |
| Aug 14, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Hudson Frederick M. | Director | Sell | 7,457 | $42.26 | $315,132.82 | -13.9% | +5.8% | - | |
| Aug 14, 2025 | BHC Bausch Health Companies Inc. | Paulson John68 | Director | Buy | 34,721,118 | $9.00 | $312,490,062.00 | +96.4% | -7.6% | - | |
| Aug 14, 2025 | PLNH Planet 13 Holdings Inc. | Fraser Lee | Chief Administrative Officer | Sell | 100,000 | $0.29 | $28,910.00 | -98.2% | - | - | |
| Aug 14, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Sensenig Bethany | Director | Sell | 5,369 | $42.25 | $226,840.25 | -100% | +5.8% | - | |
| Aug 14, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Malley Thomas67 | Director | Sell | 177,769 | $32.96 | $5,859,815.05 | -82.5% | +21.9% | - | |
| Aug 13, 2025 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 400 | $88.87 | $35,548.00 | -0.5% | -0.2% | - | |
| Aug 13, 2025 | LLY Eli Lilly & Co | Van Naarden Jacob | EVP &Pres., Lilly Oncology | Buy | 1,000 | $647.36 | $647,360.00 | +5.1% | +49.7% | - | |
| Aug 13, 2025 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 4,861 | $38.03 | $184,880.84 | -4.5% | +18.4% | - | |
| Aug 13, 2025 | LNTH Lantheus Holdings, Inc. | Blanchfield Paul54 | President | Sell | 3,060 | $53.57 | $163,924.20 | -2.7% | -0.8% | - | |
| Aug 13, 2025 | BCRX Biocryst Pharmaceuticals Inc | Heggie Theresa | Director | Sell | 70,000 | $8.51 | $595,868.00 | -51.7% | -15.2% | - | |
| Aug 13, 2025 | COLL Collegium Pharmaceutical, Inc | Rubric Capital Management LP | 10% Owner | Sell | 25,000 | $37.85 | $946,250.00 | -0.8% | +18.4% | - | |
| Aug 13, 2025 | LLY Eli Lilly & Co | Alvarez Ralph | Director | Buy | 758 | $660.25 | $500,472.53 | New | +49.7% | - | |
| Aug 13, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,581 | $48.05 | $556,419.57 | -9.0% | -17.8% | - | |
| Aug 13, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina53 | Chief Legal Officer | Sell | 30,000 | $8.20 | $246,148.50 | -8.4% | +52.8% | - | |
| Aug 13, 2025 | BHC Bausch Health Companies Inc. | Paulson John68 | Director | Buy | 3,243,049 | $6.56 | $21,267,730.74 | +3.1% | -5.0% | - | |
| Aug 12, 2025 | LLY Eli Lilly & Co | Sulzberger Gabrielle | Director | Buy | 117 | $641.18 | $75,018.29 | +4.5% | +51.2% | - | |
| Aug 12, 2025 | ANIP Ani Pharmaceuticals Inc | Rowland Thomas Andrew | SVP, Head - Established Brands | Sell | 4,975 | $85.71 | $426,407.25 | -10.9% | +0.7% | - | |
| Aug 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Shah Nikita53 | Executive Vice President | Sell | 50,000 | $9.04 | $452,000.00 | -12.9% | +27.3% | - | |
| Aug 12, 2025 | ANIP Ani Pharmaceuticals Inc | Lalwani Nikhil66 | President &CEO | Sell | 56,960 | $85.93 | $4,894,572.80 | -12.2% | +0.7% | - | |
| Aug 12, 2025 | LLY Eli Lilly & Co | Fyrwald J Erik | Director | Buy | 1,565 | $642.33 | $1,005,242.35 | +1.1% | +51.2% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.